Cargando…

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni

BACKGROUND: As plans to expand mass drug treatment campaigns to fight schistosomiasis form, worries about reliance on praziquantel as the sole available treatment motivate the investigation for novel antischistosomal compounds. Drug repurposing might be an inexpensive and effective source of novel a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panic, Gordana, Vargas, Mireille, Scandale, Ivan, Keiser, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521867/ https://www.ncbi.nlm.nih.gov/pubmed/26230921 http://dx.doi.org/10.1371/journal.pntd.0003962

Ejemplares similares

Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections
por: Keiser, Jennifer, et al.
Publicado: (2016)

Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays
por: Panic, Gordana, et al.
Publicado: (2015)

Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome
por: Schneeberger, Pierre H. H., et al.
Publicado: (2018)

Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
por: Pasche, Valérian, et al.
Publicado: (2018)

Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model
por: Abla, Nada, et al.
Publicado: (2017)

Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni
por: Cowan, Noemi, et al.
Publicado: (2015)

Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial
por: Coulibaly, Jean T, et al.
Publicado: (2017)

In silico repositioning of approved drugs against Schistosoma mansoni energy metabolism targets
por: Calixto, Nicole Melo, et al.
Publicado: (2018)

Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
por: Li, Haixia, et al.
Publicado: (2023)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasis
por: Keiser, Jennifer, et al.
Publicado: (2021)

Naturally Occurring Cardenolides Affecting Schistosoma mansoni
por: Keiser, Jennifer, et al.
Publicado: (2020)

In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium
por: Kovač, Jana, et al.
Publicado: (2017)

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
por: Feng, Jie, et al.
Publicado: (2014)

Chemometric analysis of biofluids from mice experimentally infected with Schistosoma mansoni
por: Li, Jia V, et al.
Publicado: (2011)

Evaluation of the Clinitek®, a point-of-care urinalysis system for the measurement of clinically significant urinary metabolites and detection of haematuria in Schistosoma haematobium infected children in southern Côte d’Ivoire
por: Panic, Gordana, et al.
Publicado: (2019)

Combination Anthelmintic/Antioxidant Activity Against Schistosoma Mansoni
por: Gouveia, Maria João, et al.
Publicado: (2019)

The Activity of Plant Crude Extracts against Schistosoma mansoni
por: Basha, Hirut, et al.
Publicado: (2021)

Imatinib activity on Schistosoma mansoni
por: Katz, Naftale, et al.
Publicado: (2013)

Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni
por: Di Bello, Elisabetta, et al.
Publicado: (2022)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020)

Distinct Schistosoma mansoni-Specific Immunoglobulin Subclasses Are Induced by Different Schistosoma mansoni Stages—A Tool to Decipher Schistosoma mansoni Infection Stages
por: Arndts, Kathrin, et al.
Publicado: (2021)

Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial
por: Coulibaly, Jean T., et al.
Publicado: (2018)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

The cercarial glycocalyx of Schistosoma mansoni
Publicado: (1985)

CARBOHYDRATE METABOLISM OF SCHISTOSOMA MANSONI
por: Bueding, Ernest
Publicado: (1950)

Chlorination of Schistosoma mansoni cercariae
por: Braun, Laura, et al.
Publicado: (2020)

Natural Perylenequinone Compounds as Potent Inhibitors of Schistosoma mansoni Glutathione S-Transferase
por: Otarigho, Benson, et al.
Publicado: (2023)

Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds
por: Pavani, Thaís F. A., et al.
Publicado: (2023)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for Schistosoma mansoni and S. haematobium
por: Coulibaly, Jean T., et al.
Publicado: (2012)

Validation of a human-serum-based in vitro growth method for drug screening on juvenile development stages of Schistosoma mansoni
por: Buchter, Valentin, et al.
Publicado: (2021)

High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni
por: Mansour, Nuha R., et al.
Publicado: (2016)

Bioactivity of Farnesyltransferase Inhibitors Against Entamoeba histolytica and Schistosoma mansoni
por: Probst, Alexandra, et al.
Publicado: (2019)

Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens
por: Hind, Charlotte K., et al.
Publicado: (2019)

In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs
por: Elmorsy, Mohammad A., et al.
Publicado: (2021)

In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria
por: Peyclit, Lucie, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_45v9mmmhsdd0sv4pemth9gti5v